Medtronic upgraded to Outperform at Credit Suisse

Credit Suisse upgraded Medtronic Inc (NYSE: MDT) from “neutral” to “outperform.” Credit Suisse also added MDT to its Focus List and raised the target price for MDT from $41 to $49. According to Credit Suisse, the base business of MDT was stabilizing and the risk/reward profile of MDT stocks was compelling.


There are 0 comments
Please note that comments may take up to one hour before they get published on the site. Please check back later to see your comments.

Post new comment

The content of this field is kept private and will not be shown publicly.